Pharmacokinetics, safety, and efficacy of APF530 (Extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: Results of two Phase II trials

Cancer Management and Research

Volumn 7, Issue , 2015, Pages 83-92

  Gabrail, Nashat ^a   Yanagihara, Ronald ^b   Spaczyński, Marek ^c   Cooper, William ^d   O’Boyle, Erin ^e   Smith, Carrie ^a   Boccia, Ralph ^f  

^a Gabrail Cancer Center   (United States)

^b Saint Louise Regional Hospital   (United States)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d TFS International   (United States)

^e FIBROGEN INC   (United States)

^f Center for Cancer and Blood Disorders   (United States)

Author keywords

Cancer; Chemotherapy induced nausea and vomiting; Subcutaneous

Indexed keywords

GRANISETRON;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; CANCER FATIGUE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

EID: 84936972898     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S72626     Document Type: Article

References (21)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis - v2.2014. Fort Washington, PA: National Comprehensive Cancer Network; 2014. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive. Accessed November 19, 2014.
2. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1): 103-109.
3. Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
4. Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21 Suppl 5:v232-v243.
5. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008;5(1):32-43.
6. Raftopoulos H, Cooper W, O’Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer. Epub September 2, 2014.
7. Barr J, O’Boyle E, Johnson M, et al. Phase I, double-blind, placebo-controlled, ascending single subcutaneous dose, safety, tolerability, and pharmacokinetic study of sustained release granisetron (APF530) [abstract e20587]. J Clin Oncol. 2013;31(Suppl):e20587.
8. Mason J, Boon TE, O’Boyle E, Dietz AJ. Comparison of the effects of subcutaneous APF530, intravenous granisetron, moxifloxacin, and placebo on the QT interval in humans [abstract e20539]. J Clin Oncol. 2013;31(Suppl).
9. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004;15:330-337.
10. ® (Granisetron Transdermal System) [prescribing information]. Bridgewater, NJ: ProStrakan Inc; 2014. Available from: http://www.sancuso.com/forms/SANCUSO-Full_PI.pdf. Accessed November 19, 2014.
11. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10): 1609-1617.
12. ® (granisetron hydrochloride) injection for intravenous use [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2011.
13. Mason JW, Selness DS, MoonTE, O’Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res. 2012;18(10):2913-2921.
14. fda.gov [homepage on the Internet]. Safety: Kytril (granisetron hydrochloride) injection, tablets and oral solution [FDA drug safety communication]. US Food and Drug Administration; 2009 [updated October 21, 2009]. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm187526.htm. Accessed October 7, 2014.
15. ® (granisetron hydrochloride) tablets oral solution [prescribing information]. South San Francisco, CA: Genentech, Inc; 2011. Available from: http://www.gene.com/download/pdf/kytril_injection_prescribing. pdf. Accessed November 19, 2014.
16. Upward JW, Arnold BD, Link C, Pierce DM, Allen A, Tasker TC. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer. 1990;26 Suppl 1:S12-S15.
17. Carmichael J, Philip PA, Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol. 1995;37(1-2):134-138.
18. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996;37(5):502-504.
19. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer. 2003;39(7):927-931.
20. Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2004;53(2):123-128.
21. Boccia RV, Cooper W, O’Boyle E. Sustainability of antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens: Results of a randomized Phase III trial [abstract 9626]. J Clin Oncol. 2013;31(Suppl):9626.